ORCID as entered in ROS

Select Publications
Dore GJ; Correll PK; Li Y; Kaldor JM; Cooper DA; Brew BJ, 1999, 'Changes to AIDS dementia complex in the era of highly active antiretroviral therapy', AIDS, 13, pp. 1249 - 1253
Dore GJ; Cooper DA; Barrett C; Goh L; Thakrar B; Atkins M, 1999, 'Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR)', Journal of Infectious Diseases, 180, pp. 607 - 613
Dore GJ; Law MG; Kaldor JM, 1999, 'Prevalence of hepatitis C virus infection in the United States', New England Journal of Medicine, pp. 2093 - 2094 (lett
Mcneil PM; Dore GJ, 1999, 'Should research ethics change at the border?', Medical Journal of Australia, 171, pp. 168 - (letter)
Dore GJ; Pritchard-Jones J; Fisher D; Law MG, 1999, 'Who's at risk: risk factors for HCV infection in Australia', Australian Family Physician, pp. 8 - 13
Wettstein AR; Dore G; Murphy C; Edwards PD, 1998, 'HIV related cholangiopathy (HIVRC): Is endoscopic biliary sphincterotomy (EBS) an effective therapy?', Gastrointestinal Endoscopy, 47
McNeill PM, 1998, 'Should research ethics change at the border?', Medical Journal of Australia, 169, pp. 509 - 510, http://dx.doi.org/10.5694/j.1326-5377.1998.tb123394.x
Collignon P; Dore GJ; Li Y; Plant AJ; Kaldor JM, 1998, 'Trends in infectious disease mortality rates (multiple letters) [3]', Medical Journal of Australia, 169, http://dx.doi.org/10.5694/j.1326-5377.1998.tb126845.x
Dore GJ; Kaldor JM; McCaughan GW, 1998, 'Polymerase chain reaction as marker of infectivity in people with hepatitis C - Summary vertical transmission rates may be misleading - Reply', BRITISH MEDICAL JOURNAL, 316, pp. 554 - 554, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000072097400048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Thomas S; Hall A; Newell ML; Dore GJ; Kaldor JM; McCaughan GW, 1998, 'Polymerase chain reaction as marker of infectivity in people with hepatitis C (multiple letters) [5]', British Medical Journal, 316, pp. 553 - 554
Hira SK; Dore GJ; Sirisanthana T, 1998, 'Clinical spectrum of HIV/AIDS in the Asia-Pacific region.', AIDS (London, England), 12 Suppl B
Dore GJ, 1998, 'Chronic hepatitis C infection: a disease ideally suited to management in the primary care setting', Australian Family Physician, pp. 791 - 793
McDonald AM; French R; Dore GJ; Hamernik E; Kippax SC; Ashton LJ, 1998, 'Epidemiological and social research findings reported at the 12th World AIDS Conference, Geneva 1998', Australian HIV Surveillance Report, 14, pp. 1 - 9
Crofts JN; Dore GJ; Kaldor JM; Law MG; Wodak AD; Et A, 1998, 'Estimates and projections of the hepatitis C virus epidemic in Australia', ION Meeting Proceedings
Dore GJ; Brown TA; Tarantola D; Kaldor JM, 1998, 'HIV and AIDS in the Asia-Pacific region: an epidemiological overview', AIDS, 12, pp. S1 - S10
Van Beek IA; Dwyer RG; Dore GJ; Luo K; Kaldor JM, 1998, 'Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study', British Medical Journal: International, pp. 433 - 437
Dore GJ; Grulich AE; Law MG; Brew BJ; Kaldor JM, 1998, 'Kaposi¿s sarcoma and protection from AIDS dementia complex', AIDS, 12, pp. 2354 - 2355
Dore GJ; Kaldor JM; Mccaughan GW, 1998, 'Polymerase chain reaction as marker of infectivity in people with hepatitis C', British Medical Journal: International, pp. 553 - 554
Dore GJ, 1998, 'Report from the 4th International Conference on AIDS in Asia and the Pacific', Noah's Arc
Dore GJ; Kaldor JM, 1998, 'Sexually transmissible diseases surveillance in Australia: towards a coordinated national system', Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended, pp. 49 - 52
Dore GJ; Li YW; Plant AJ; Kaldor JM, 1998, 'Trends in infectious disease mortality in Australia, 1979-1994', Medical Journal of Australia, 168, pp. 601 - 604
Dore GJ; Li YW; Plant AJ; Kaldor JM, 1998, 'Trends in infectious disease mortality rates', Medical Journal of Australia, 169, pp. 444 - 445
Aguado JM; Pulido F; Dore GJ; Law MG; Kaldor JM; Gordin F; Matts J, 1997, 'Isoniazid prophylaxis for high-risk patients with anergy and HIV infection [4] (multiple letters)', New England Journal of Medicine, 337, pp. 1696 - 1697, http://dx.doi.org/10.1056/NEJM199712043372316
Dore GJ; Law MG; Kaldor JM, 1997, 'Isoniazid prophylaxis for high-risk patients with anergy and HIV infection.', The New England journal of medicine, 337, pp. 1697
Dore GJ; Law MG; Brew BJ, 1997, 'Prospective analysis of seizures occurring in human immunodeficiency virus type-1 infection', Journal of Neuro-AIDS, 1, pp. 59 - 69, http://dx.doi.org/10.1300/J128v01n04_06
Gray JA; Dore GJ; Li Y; Supawitkul S; Effler P; Kaldor JM, 1997, '"HIV-1 Infection among Female Commercial Sex Workers in Rural Thailand."', Studies in Family Planning, 28, pp. 168 - 168, http://dx.doi.org/10.2307/2138125
Dore GJ; Law MG; Kaldor JM, 1997, 'A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis', New England Journal of Medicine, pp. 315 - 320
Gray JA; Dore GJ; Li Y; Supawitkul S; Effler P; Kaldor JM, 1997, 'HIV-1 infection among female commercial sex workers in rural Thailand', AIDS, 11, pp. 89 - 94
Dore GJ; Kaldor JM; Mccaughan GW, 1997, 'Systematic review of role of polymerase chain reaction in defining infectiousness among people with hepatitis C virus', British Medical Journal: Clinical Research, pp. 333 - 337
Dore GJ; Hoy JF; Mallal SS; Li YW; Mijch AM; French MA; Cooper DA; Kaldor JM, 1997, 'Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS Cohort', Journal of acquired immune deficiency syndrome and human retrovirology, 16, pp. 39 - 43
Dore GJ; Kaldor JM; Ungchusak K; Mertens TE, 1996, 'Epidemiology of HIV and AIDS in the Asia-Pacific region', Medical Journal of Australia, 165, pp. 494 - 498, http://dx.doi.org/10.5694/j.1326-5377.1996.tb138615.x
Dore GJ; Kaldor JM; Ungchusak K; Mertens TE, 1996, 'Managing HIV .9. HIV in Asia and the Pacific - Epidemiology of HIV and AIDS in the Asia-Pacific region', MEDICAL JOURNAL OF AUSTRALIA, 165, pp. 494 - 498, http://dx.doi.org/10.5694/j.1326-5377.1996.tb138615.x
Dore GJ; Li YW; Mallal SA; Hoy JF; Mijch AM; French MA; Cooper DA; Kaldor JM; Grulich AE, 1996, 'Declining incidence and later occurrence of Kaposi`s sarcoma among people with AIDS in Australia: the Australian AIDS cohort', AIDS, 10, pp. 1401 - 1406
Couldwell D; Dore GJ; Harkness JL; Marriott D; Cooper DA; Edwards RJ; Li YW; Kaldor JM, 1996, 'Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room', AIDS, 10, pp. 521 - 525
Law MG; Dore GJ; McDonald AM; Kaldor JM, 1996, 'The use of back-projection to estimate HIV prevalence in pregnant women', Paediatric AIDS and HIV Infection, pp. 331 - 336
Dore GJ; Marriot DJ; Duflou J, 1995, 'Clinico-pathological study of cytomegalovirus infection (CMV) is AIDS autopsies: under-recognition of CMV pneumonitis and CMV adrenalitis', Australian and New Zealand Journal of Medicine, pp. 503 - 506
Dore GJ; Marriott D; Hing MC; Harkness JL; Field AS, 1995, 'Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with Human Immunodeficiency virus: Response to therapy with Albendazole', Clinical Infectious Diseases, pp. 70 - 76
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J, 2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study', in International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2022.103706
Conway A; Treloar C; Crawford S; Degenhardt L; Dore GJ; Farrell M; Grebely J; Marshall AD, 2021, '"WE'VE HAD A CIRCUIT BREAKER FOR AN OLD DOGMA OF MORE THAN 20 YEARS": CHANGES TO OPIOID AGONIST TREATMENT SERVICES DURING COVID-19, THE CHOICE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200148&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Amin J; Christmass M; Dunlop AJ; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Dore GJ; Treloar C; Grebely J, 2021, 'OPIOID OVERDOSE AND NALOXONE ACCESS AMONG PEOPLE WHO RECENTLY USED OPIOIDS OR RECEIVED OPIOID AGONIST TREATMENT IN AUSTRALIA: THE ETHOS ENGAGE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200149&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Casey J; MacParland S; Zahoor A; Janssen HLA; Matthews G; Marks P; Grebely J; Dore G; Hansen BE; Kaul R; Chua C; Gehring AJ; Feld JJ, 2020, 'RESTORATION OF HCV-SPECIFIC T CELLS FOLLOWING DAA THERAPY IN ACUTE HCV INFECTION-SUPPORT FOR TREATMENT OF ACUTE INFECTION.', in HEPATOLOGY, WILEY, ELECTR NETWORK, pp. 613A - 614A, presented at Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 November 2020 - 16 November 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000574027002142&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Papaluca T; Roberts S; Strasser S; Stuart K; New K; Farrell G; Dore G; Wigg A; Woodward A; Wade A; George J; Sinclair M; McGarity B; Fisher AL; Sawhney R; Wilson M; Valiozis I; Levy M; Tse E; Ahlenstiel G; Haque M; Prewett E; Sievert W; Sood S; O'Beirne J; Thomas J; Hazeldine S; Valaydon Z; Douglas M; Bowden S; O'Keefe J; Holmes J; Thompson A, 2020, 'Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis', in JOURNAL OF HEPATOLOGY, ELSEVIER, pp. S363 - S363, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587001118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Marshall AD; Grebely J; Dore GJ; Treloar C, 2019, 'BARRIERS AND FACILITATORS TO ENGAGING IN HEPATITIS C MANAGEMENT AND DIRECT-ACTING ANTIVIRAL THERAPY AMONG GENERAL PRACTITIONERS AND DRUG AND ALCOHOL SPECIALISTS: THE PRACTITIONER EXPERIENCE', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S9 - S9, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Papaluca T; New K; Strasser S; Stuart K; Dore G; Farrell G; George J; Jeffrey G; O'Beirne J; Sinclair M; Wade A; Ahlenstiel G; Hazeldine S; Wigg A; Sheikh K; Woodward A; Weltman M; Valiozis I; Mcgarity B; Fisher L; Levy M; Tse E; Wilson M; Thomas J; Lee A; Sawhney R; Sievert W; Sood S; Cheng W; Roberts S; Thompson A, 2019, 'Efficacy and safety of sofosbuvir, velpatasvir, and voxilaprevir in NS5A-experienced patients with advanced liver disease or prior liver transplantation: The first Australian real-world experience', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 72 - 73, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Artenie AA; Cunningham E; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Applegate TL; Dillon JF; Fraser C; Gane E; Litwin AH; Marks P; Matthews GV; Quiene S; Thurnheer MC; Weltman M; Dore G; Bruneau J; Grebely J, 2018, 'Drug and alcohol use patterns during and following treatment with sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use: Insights from trajectory analyses', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, pp. 31 - 32, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lamoury F; Bajis S; Martinez D; Mowat Y; Jayasinghe I; Martinez M; Cunningham P; Catlett B; Jacka B; Marks P; Grebely J; Cloherty G; Dore G; Applegate T, 2018, 'Evaluation of a hepatitis C virus core antigen assay in dried-blood spots: a cohort study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S317 - S318, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30854-7
Lamoury F; Bajis S; Hajarizadeh B; Marshall A; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing D; Kleman M; Cunningham P; Dore G; Applegate T; Grebely J, 2018, 'Evaluation of the Xpert fingerstick HCV viral load assay', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S167 - S167, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30546-4
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin N; Mchutchison JG; Brainard D; Treloar C; Lloyd A; Dore G, 2018, 'Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S187 - S188, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30587-7
Morley KC; Baillie AJ; Dore GJ; Phung N; Fraser I; Furneaux-Bate A; Haber PS, 2017, 'A RANDOMISED CLINICAL TRIAL OF BACLOFEN FOR THE TREATMENT OF ALCOHOL DEPENDENCE', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 53 - 53, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500138&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Feld JJ; Wyles D; Sulkowski MS; Ni L; Llewellyn J; Mir H; Sajed N; Stamm LM; Hyland R; McNally J; Brainard D; Jacobson I; Zeuzem S; Bourliere M; Foster G; Afdhal N; Dore GJ, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRAL THERAPIES FOR HEPATITIS C VIRUS INFECTION IN PATIENTS RECEIVING OPIOID SUBSTITUTION THERAPY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 34 - 35, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500086&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1